Guardant Health (NASDAQ:GH) Director Musa Tariq Sells 116 Shares of Stock

Guardant Health, Inc. (NASDAQ:GH) Director Musa Tariq sold 116 shares of the company’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $95.96, for a total value of $11,131.36. Following the sale, the director directly owned 8,662 shares of the company’s stock, valued at $831,205.52. The trade was a 1.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Musa Tariq also recently made the following trade(s):

• On Thursday, April 16th, Musa Tariq sold 116 shares of Guardant Health stock. The shares were sold at an average price of $84.83, for a total transaction of $9,840.28.
• On Wednesday, March 18th, Musa Tariq sold 348 shares of Guardant Health stock. The stock was sold at an average price of $88.09, for a total transaction of $30,655.32.

Guardant Health Trading Up 2.6%

NASDAQ GH opened at $98.19 on Wednesday. Guardant Health, Inc. has a 1 year low of $36.36 and a 1 year high of $120.74. The company has a fifty day simple moving average of $89.50 and a 200 day simple moving average of $98.46. The company has a market cap of $13.02 billion, a P/E ratio of -28.96 and a beta of 1.48.

Guardant Health (NASDAQ:GH) last released its earnings results on Thursday, February 19th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The business had revenue of $281.27 million for the quarter, compared to analysts’ expectations of $269.74 million. Guardant Health’s revenue was up 39.4% on a year-over-year basis. During the same period last year, the company posted ($0.62) earnings per share. Equities research analysts forecast that Guardant Health, Inc. will post -2.87 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have commented on GH shares. Wells Fargo & Company lifted their price target on Guardant Health from $120.00 to $125.00 and gave the stock an “overweight” rating in a research report on Friday, February 20th. Leerink Partners upped their target price on shares of Guardant Health from $170.00 to $180.00 and gave the company an “outperform” rating in a research note on Friday, February 20th. Robert W. Baird began coverage on shares of Guardant Health in a research report on Tuesday, February 17th. They issued an “outperform” rating and a $120.00 price target on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $135.00 price objective on shares of Guardant Health in a research report on Tuesday, May 12th. Finally, Raymond James Financial reiterated an “outperform” rating and issued a $129.00 target price on shares of Guardant Health in a research note on Monday, February 23rd. Nineteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $129.42.

Institutional Trading of Guardant Health

Several institutional investors have recently made changes to their positions in the business. V Square Quantitative Management LLC bought a new position in Guardant Health during the fourth quarter worth about $27,000. Chesapeake Asset Management LLC bought a new stake in shares of Guardant Health in the 4th quarter valued at approximately $28,000. Thurston Springer Miller Herd & Titak Inc. bought a new stake in shares of Guardant Health in the 4th quarter valued at approximately $31,000. Elyxium Wealth LLC acquired a new position in shares of Guardant Health in the 4th quarter worth approximately $35,000. Finally, Parallel Advisors LLC raised its holdings in shares of Guardant Health by 164.7% in the 4th quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after buying an additional 219 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.